Ultrasound-Measured Cortical Bone Porosity Linked to Nontraumatic Fracture in Postmenopausal Women
Cortical bidirectional axial transmission measurements may be useful for fracture risk assessment in postmenopausal women.
Osteoporosis
Abaloparatide Significantly Reduces Fracture Risk in Women With Postmenopausal Osteoporosis
A meta-analysis showed that abaloparatide treatment reduces the risk for vertebral, nonvertebral, and wrist fractures in postmenopausal women with osteoporosis compared with placebo or other medical treatments.
Outcomes of FRAX-Predicted Risk Treatment Thresholds in Women
Participants included in the study were women aged 40 and older, with a baseline bone mineral density measure after 1996, and with at least a 5-year follow-up.
Oral Contraceptives Offer Some Protection Against Bone Loss in Anorexia Nervosa
For young women with anorexia nervosa, oral contraceptives may limit bone loss.
Most Osteoporosis Guidelines Do Not Discuss Patient Beliefs, Preferences
Less than 40 percent of osteoporosis clinical practice guidelines include any mention of patients’ beliefs, values, or preferences.
FDA Approves First-in-Class Sclerostin-Inhibitor for Postmenopausal Women at High Risk for Fracture
The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.
Testosterone Replacement in Congenital Hypogonadotropic Hypogonadism Has Limited Effects on Bone Health
Testosterone replacement therapy prevents further bone loss at the lumbar and femoral levels in patients with congenital hypogonadotropic hypogonadism, but it does not reliably elevate bone mineral density out of the osteopenic/osteoporotic range.
Treatments for Preventing Fracture in Postmenopausal Women Compared
Overall, treatments that were associated with the greatest relative risk reduction in fragility fractures included teriparatide, abaloparatide, denosumab, romosozumab and most bisphosphonate.
Rapid Bone Mineral Density Declines Increase Vertebral Fracture Risk in COPD
In elderly patients with COPD, rapid decline in bone mineral density is associated with an increased risk for vertebral fracture.
Managing Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline
Multiple pharmacologic therapies have been shown to reduce fracture rates in postmenopausal women with acceptable safety profiles
Next post in ENDO 2019
